Immunotherapy with ponezumab for probable ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
Author(s) :
Leurent, Claire [Auteur]
Goodman, James A. [Auteur]
Zhang, Yao [Auteur]
He, Ping [Auteur]
Polimeni, Jonathan R. [Auteur]
Gurol, Mahmut Edip [Auteur]
Lindsay, Monica [Auteur]
Frattura, Linda [Auteur]
Sohur, Usharbudh Shivraj [Auteur]
Viswanathan, Anand [Auteur]
Bednar, Martin M. [Auteur]
Smith, Eric E. [Auteur]
Greenberg, Steven M. [Auteur]
Goodman, James A. [Auteur]
Zhang, Yao [Auteur]
He, Ping [Auteur]
Polimeni, Jonathan R. [Auteur]
Gurol, Mahmut Edip [Auteur]
Lindsay, Monica [Auteur]
Frattura, Linda [Auteur]
Sohur, Usharbudh Shivraj [Auteur]
Viswanathan, Anand [Auteur]
Bednar, Martin M. [Auteur]
Smith, Eric E. [Auteur]
Greenberg, Steven M. [Auteur]
Journal title :
Annals of clinical and translational neurology
Abbreviated title :
Ann Clin Transl Neurol
Volume number :
6
Pages :
795-806
Publication date :
2019-04-01
ISSN :
2328-9503
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of ββ1-40
Thirty-six participants aged 55-80 years with probable CAA received intravenous placebo (nn
The mean change from baseline to Day 90 was ...
Show more >Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of ββ1-40 Thirty-six participants aged 55-80 years with probable CAA received intravenous placebo (nn The mean change from baseline to Day 90 was 0.817 (ponezumab) and 0.958 (placebo): a mean ratio of 0.852 (90% CI 0.735-0.989) representing a trend towards reduced Ponezumab was safe and well-tolerated. The ponezumab group showed a trend towards treatment effect at Day 90 that was opposite to the hypothesized direction. The prespecified efficacy criteria were thus not met.Show less >
Show more >Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of ββ1-40 Thirty-six participants aged 55-80 years with probable CAA received intravenous placebo (nn The mean change from baseline to Day 90 was 0.817 (ponezumab) and 0.958 (placebo): a mean ratio of 0.852 (90% CI 0.735-0.989) representing a trend towards reduced Ponezumab was safe and well-tolerated. The ponezumab group showed a trend towards treatment effect at Day 90 that was opposite to the hypothesized direction. The prespecified efficacy criteria were thus not met.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2019-11-27T13:38:34Z